Hyloris Launches Non-Opioid Painkiller Maxigesic® IV in the U.S. and Canada

27 February, 2024 | 2 Min Read

tickers: HKMPF

tickers affected by this

ticker	polarity	why?
HKMPF	positively	The positive launch of Maxigesic® IV in the U.S. and approval in Canada is likely to have a favorable impact on the ticker HKMPF due to the increased market potential and revenue from the successful introduction of this innovative pain management solution in these key regions.

our strategies and bots using these tickers

None so far…

summary

Hyloris Announces Launch of Maxigesic® IV in the U.S. and Approval in Canada

Liège, Belgium - February 27, 2024: Hyloris Pharmaceuticals SA, a specialty biopharma company, revealed the launch of Maxigesic® IV in the U.S. under the trade name Combogesic® IV by its partner Hikma Pharmaceuticals. This potent non-opioid painkiller aims to revolutionize pain management, offering effective relief and a non-addictive alternative to opioids. Canada Approval: Furthermore, Maxigesic® IV has secured marketing approval in Canada, where the opioid crisis continues to pose significant challenges. With 22 Canadians succumbing daily to apparent opioid toxicity, there is a pressing need for safe and efficient pain management solutions post-surgery, bridging the gap between NSAIDs and opioids. Addressing the Opioid Crisis: The U.S. also grapples with a severe opioid pandemic, with chronic opioid use post-surgery leading to adverse outcomes. The introduction of Maxigesic® IV aims to combat this issue by providing a potent combination of paracetamol and ibuprofen, offering superior pain relief without the risks associated with opioids. Clinical Efficacy: Based on a Phase 3 trial, Maxigesic® IV demonstrated faster onset of action and superior pain relief compared to individual paracetamol and ibuprofen IV treatments. Additionally, the combination therapy resulted in reduced opioid consumption, highlighting its potential in mitigating the opioid crisis. Future Prospects: With approvals in over 40 countries and ongoing marketing in 20 countries, Hyloris Pharmaceuticals is positioned to make a significant impact in global pain management. The company’s focus on innovating existing medications to meet healthcare needs emphasizes its commitment to delivering safe and effective treatments. Conclusion: The launch of Maxigesic® IV in the U.S. and approval in Canada mark a pivotal moment in the evolution of non-opioid pain management strategies. Hyloris Pharmaceuticals’ dedication to addressing unmet medical needs underscores the importance of providing clinicians and patients with alternative solutions that prioritize safety and efficacy in pain management.